Mapi Pharma Ltd. received an additional $20 million investment from Mylan to support Phase III clinical study progress to bring Glatiramer Acetate (GA) Depot, a once-monthly injection for the treatment of relapsing-remitting multiple sclerosis (RRMS), to market in the U.S.

Mapi initiated the Phase III study in October and is a 1,000 patient pivotal clinical study designed to support a New Drug Application (NDA) with the FDA. Mapi is also building capacity at its facility to supply GA-Depot for commercial sale, pending approval.

In the U.S., a study funded by the National MS Society estimates that nearly 1 million people are living with MS. Relapsing-remitting MS accounts for approximately 85% of initial MS diagnoses. According to recent market research, the global multiple sclerosis drugs market is anticipated to expand at a CAGR of 6.7%, and reach $39 billion by the end of 2026.